ESCO LIFESCIENCES INVESTMENTS PTE. LTD. Business Review
Business Overview
TrustScore Analysis
Our preliminary analysis has revealed key insights about ESCO LIFESCIENCES INVESTMENTS PTE. LTD.'s performance and market presence. Here‘s a summary of our findings:
Positive highlights
Has been operational for a few years
Negative highlights
- No employer brand presence on career platforms
- May not have contact information online
- No official business profile found on major search engines
Corporate Information
64202
Other holding companies
Contact Information for ESCO LIFESCIENCES INVESTMENTS PTE. LTD.
ESCO LIFESCIENCES INVESTMENTS PTE. LTD.'s Business Reviews
No reviews available
Review This Business
Recently transacted with ESCO LIFESCIENCES INVESTMENTS PTE. LTD.?
How would you rate your overall satisfaction?
Be a part of the community and help others make informed decisions by sharing your experience. Your feedback not only helps the business improve but also assists other customers in choosing the best services and products available.
Public Preview of ESCO LIFESCIENCES INVESTMENTS PTE. LTD.
This is only a preview of the TrustScore results for ESCO LIFESCIENCES INVESTMENTS PTE. LTD., showcasing a few facets of its business that we have analysed.
Foundational Stage
A young brand or company in the early stage of organisation structures, framework, processes, workflow, systems.
Key Characteristics
- Defining Core Identity: ESCO LIFESCIENCES INVESTMENTS PTE. LTD. is likely still defining its mission, vision and values.
- Building Awareness: Working to establish recognition among its target audience and identifying opportunities in the other holding companies sector.
- Limited Resources: Often operating with a small team, budget, or customer base. May not yet have a strong social media presence or widespread advertising.
- Focus on Differentiation: Still trying to carve out a unique position in the market, or have a unique selling proposition. They are gathering feedback and iterating on their offerings.
Why It Matters
- These potential brands often represent innovation and creativity.
- They often bring fresh ideas to the market and have the opportunity to grow into influential players if they successfully establish their identity and connect with their audience.
The company's address in use by other companies, may raise concerns about the company's credibility and legitimacy. ESCO LIFESCIENCES INVESTMENTS PTE. LTD. has been operational for a few years, showing some level of stability. While it shows some level of stability, it may still be in the process of establishing its reputation and credibility.
ESCO LIFESCIENCES INVESTMENTS PTE. LTD. has no presence on career platforms and provides no public information about its work environment or employee satisfaction. This lack of transparency may indicate less focus on employee well-being or difficulty in attracting talent, potentially impacting ESCO LIFESCIENCES INVESTMENTS PTE. LTD.'s long-term success.
The company is not blacklisted by CaseTrust, which is a positive indicator of its credibility. The company is not on the MAS Enforcement List, which is a positive indicator of its compliance with financial regulations.
ESCO LIFESCIENCES INVESTMENTS PTE. LTD. may not have accessible contact information online, which dilutes engagement and credibility. The company has no official business profile on major search engines. This absence makes it difficult for potential customers to verify the company's legitimacy or get in touch, potentially raising suspicions about its credibility.
Content Locked
Sign in to view the analysis and detailed metrics for ESCO LIFESCIENCES INVESTMENTS PTE. LTD.
Sign In to ContinueAssociated News for ESCO LIFESCIENCES INVESTMENTS PTE. LTD.
1. Esco Lifesciences raises US$200 million ahead of potential listing The Singapore-based company, which supplies life sciences tools for the healthcare industry, got backing from GIC in its Series A round, according to a source. The funding was led by US-based healthcare investment firm Vivo Capital and Denmark-based life science investor Novo Holdings, the venture arm of Novo Nordisk Foundation.
1. Esco Lifesciences raises US$200 million ahead of potential listing The Singapore-based company, which supplies life sciences tools for the healthcare industry, got backing from GIC in its Series A round, according to a source. The funding was led by US-based healthcare investment firm Vivo Capital and Denmark-based life science investor Novo Holdings, the venture arm of Novo Nordisk Foundation.
Singapore Biopharma Manufacturer Raises $200 Million Series A | BioSpace
Singapore-based Esco Lifesciences closed a $200 million oversubscribed Series A financing and crossover round that will enable the company that provides life sciences tools and services to expand its toehold in China and the United States. Esco is a manufacturer of laboratory and biopharma equipment and IVF medical devices. The company has four different divisions, Scientific, Medical, Healthcare, and Aster, which offers “mission-critical equipment and advanced solutions” to laboratories, clinics, and bio-pharma production sites in over 100 countries. The company employs more than 1,300 people across the globe. It has offices in more than 100 companies, including eight manufacturing and R&D hubs in the US, Europe, the UK, China, and Singapore. The financing round is the largest private fundraising round by an Asia-based life sciences tools company, Esco said in its announcement.
Novo Holdings, Vivo lead a record $200M raise for a Singapore-based tools player with plans for a Boston hub, new deals
Close to a year after putting a foot down in Singapore, Novo Holdings has spotted an Asia-based player worth betting a big chunk of its “patient capital” on. The Danish group is co-leading a $200 million Series A for Esco Lifesciences Group — setting a new record for life sciences tools companies in the region, according to the investor, and funding a sprint toward “Esco 3.0,” where cell and gene therapy process development and manufacturing will loom large.
S'pore lab firm raises $265m from backers including GIC
Esco Lifesciences Group, a Singapore firm that pivoted from washing laboratory gowns to making high-tech equipment, has raised US$200 million (S$265 million) from some of the world's biggest healthcare investors, paving the way for a possible listing in Hong Kong this year. The funding round, led by Danish investment giant Novo Holdings and US investor Vivo Capital, also included Chinese sovereign wealth fund China Investment, according to a statement from Esco. Other new backers include Singapore's sovereign wealth fund GIC, with the fund raising giving the company a valuation of US$800 million, according to people familiar with the matter. The sources asked not to be identified as the details are not public.
27 May 2021
Novo, GIC back Singapore lab firm in US$200 million funding round
Esco Lifesciences Group, a Singapore firm that pivoted from washing lab gowns to making high-tech equipment, has raised US$200 million (S$265 million) from some of the world's biggest healthcare investors, paving the way for a possible listing in Hong Kong this year. The funding round led by Danish investment giant Novo Holdings and US investor Vivo Capital also included Chinese sovereign wealth fund China Investment, according to a statement from Esco. Other new backers include Singapore's GIC, with the fund raising giving the company a valuation of US$800 million, according to people familiar with the matter. The sources asked not to be identified as the details are not public.
27 May 2021
FAQs
Frequently Asked Questions
Have questions? We’re here to help you.
Scam.SG's TrustScore is an AI-driven engine that evaluates a business's trustworthiness by analysing data such as customer feedback, behavioral patterns, and compliance records. This comprehensive assessment results in a numerical score reflecting the entity's reliability.
Similar Companies
If you’re living in Singapore and want to enjoy your Netflix series worry-free, it’s crucial to understand how these scams work and how to protect yourself.
Navigate Singapore's evolving digital landscape with confidence. Learn how to protect your children from online scams, predators, and harmful content using the latest tools, regulations, and expert strategies tailored for 2025, with insights from IMDA, SP